US Patent No: 5,516,637

Number of patents in Portfolio can not be more than 2000

Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage

2 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a fusion protein, comprising a pilin protein or a portion thereof and a heterologous polypeptide (target protein). In a preferred embodiment it relates to a method for displaying the target protein on the outer surface of a bacterial host cell capable of forming pilus. In certain embodiments, it is desirable that the pilus is a receptor for bacteriophage attachment and infection. The F pilus is preferred.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
DADE BEHRING INC.DEERFIELD, IL1

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Huang, Grace P Miami, FL 1 113
Rhode, Peter R Miami, FL 13 188
Stinson, Jeffrey R Brookeville, MD 31 258
Wong, Hing C Weston, FL 81 411

Cited Art Landscape

Patent Info (Count) # Cites Year
 
GGMJ TECHNOLOGIES, L.L.C. (1)
* 5,348,867 Expression of proteins on bacterial surface 58 1991
 
DYAX CORP. (1)
* 5,223,409 Directed evolution of novel binding proteins 1111 1991
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
SPECTRAL DIAGNOSTICS, INC. (1)
6,475,785 Single-chain polypeptides comprising troponin I N-terminal fragments and troponin C 2 1999
 
Other [Check patent profile for assignment information] (1)
8,962,803 Antibodies against the RGM A protein and uses thereof 0 2009
 
RAMOT AT TEL-AVIV UNIVERSITY LTD. (1)
* 6,165,722 Representations of bimolecular interactions 5 1999
 
CUREDM GROUP HOLDINGS, LLC (8)
8,211,430 Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions 2 2006
7,393,919 Peptides, derivatives and analogs thereof, and methods of using same 10 2006
8,785,400 Methods and compositions relating to islet cell neogenesis 0 2007
7,714,103 Peptides, derivatives and analogs thereof, and methods of using same 5 2008
8,816,047 Compositions and methods of using proislet peptides and analogs thereof 0 2008
7,989,415 Peptides, derivatives and analogs thereof, and methods of using same 4 2009
8,383,578 Peptides, derivatives and analogs thereof, and methods of using same 1 2011
8,829,158 Peptides, derivatives and analogs thereof, and methods of using same 0 2013
 
ABBVIE DEUTSCHLAND GMBH & CO KG (2)
8,906,864 Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use 0 2006
8,895,004 Method for the treatment of amyloidoses 0 2008
 
SERONO GENETICS INSTITUTE S.A. (1)
6,867,189 Use of adipsin/complement factor D in the treatment of metabolic related disorders 5 2002
 
GEORGETOWN UNIVERSITY (1)
* 7,355,015 Matriptase, a serine protease and its applications 2 2000
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
7,041,441 Phage display of intact domains at high copy number 1 1997
 
UNIVERSITY OF ROCHESTER (4)
7,563,882 Polynucleotides encoding antibodies that bind to the C35 polypeptide 18 2003
7,750,125 Antibodies that bind to the C35 polypeptide 13 2007
7,968,688 Antibodies that bind to the C35 polypeptide 0 2009
7,879,990 Polynucleotides encoding antibodies that bind to the C35 polypeptide 0 2009
 
SANOFI (3)
8,460,667 EPHA2 receptor antagonist antibodies 1 2007
8,153,765 Anti-CD38 antibodies for the treatment of cancer 0 2007
8,668,910 Antibodies that specifically bind to the EphA2 receptor 0 2010
 
NEXUS DX, INC. (1)
* 5,981,249 Single-chain polypeptides comprising creatine kinase M and creatine kinase B 0 1998
 
IKONISYS, INC. (1)
7,885,449 System for detecting infectious agents using computer-controlled automated image analysis 0 2008
 
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (1)
7,611,858 Detection of cannabinoid receptor biomarkers and uses thereof 0 2007
 
N.o slashed.AB Immunoassay, Inc. (1)
* 5,922,537 Nanoparticles biosensor 179 1996
 
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (1)
8,680,239 Use of RGM and its modulators 0 2012
 
BUNDESREPUBLIK DEUTSCHLAND LETZTVERTRETEN DURCH DAS ROBERT-KOCH-INSTITUT VERTRETEN DURCH SEINEN PRASIDENTEN (1)
8,318,905 Antibodies for depletion of ICOS-positive cells in vivo 0 2005
 
UCB PHARMA S.A. (10)
7,736,635 Branched molecular scaffolds for linking polymer residues to biologically active moieties 0 2004
8,129,505 Comb polymers 0 2006
8,075,889 Antibody molecules having specificity for human IL-6 0 2006
7,931,900 Method for the treatment of multiple sclerosis by inhibiting IL-17 activity 2 2008
8,614,295 Antibody molecules having specificity for human OX40 0 2010
8,691,233 Antibody molecules having binding specificity for human IL-13 0 2010
8,926,977 Antibodies to the E1 extracellular loop of ion channels 0 2010
8,734,798 Function modifying NAv 1.7 antibodies 0 2010
8,486,662 DNA encoding antibody molecules having specificity for human IL-6 0 2011
8,580,265 Antibody molecules which bind IL-17A and IL-17F 0 2012
 
YALE UNIVERSITY (2)
7,297,762 Modified avian pancreatic polypeptide miniature binding proteins 0 2001
7,495,070 Protein binding miniature proteins 0 2004
 
THE MCCOMB FOUNDATION, INC. (1)
8,946,381 Compositions and uses thereof for the treatment of wounds 0 2007
 
BRISTOL-MYERS SQUIBB COMPANY (2)
7,259,002 Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof 0 2004
7,482,124 Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema 0 2006
 
MILLENNIUM PHARMACEUTICALS, INC. (3)
7,101,549 Glycoprotein VI and uses thereof 4 2004
7,597,888 Glycoprotein VI and uses thereof 4 2006
8,137,923 Glycoprotein VI and uses thereof 0 2010
 
CHILDREN'S MEDICAL CENTER CORPORATION (1)
7,125,679 Methods to screen peptide libraries using minicell display 14 2002
 
VIB VZW (1)
* 6,479,280 Recombinant phages capable of entering host cells via specific interaction with an artificial receptor 3 1999
 
TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (1)
7,294,701 Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same 2 2003
 
ABBVIE INC. (23)
7,700,739 IL-12/p40 binding proteins 2 2006
7,612,181 Dual variable domain immunoglobulin and uses thereof 42 2006
8,691,224 Anti-Aβ globulomer 5F7 antibodies 0 2006
8,497,072 Amyloid-beta globulomer antibodies 0 2006
7,915,388 Interleukin-13 binding proteins 1 2007
8,455,626 Aβ conformer selective anti-aβ globulomer monoclonal antibodies 0 2007
8,323,651 Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof 0 2009
8,258,268 Dual variable domain immunoglobulin and uses thereof 12 2009
8,822,645 Prostaglandin E2 dual variable domain immunoglobulins and uses thereof 0 2009
8,383,778 IL-1 binding proteins 1 2010
8,835,610 IL-17 binding proteins 0 2010
8,629,257 IL-12/p40 binding proteins 0 2010
8,623,358 Therapeutic DLL4 binding proteins 0 2010
8,586,714 Dual variable domain immunoglobulins and uses thereof 1 2010
8,716,450 Dual variable domain immunoglobulins and uses thereof 1 2010
8,722,855 Dual variable domain immunoglobulins and uses thereof 0 2010
8,420,083 Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof 0 2010
8,604,177 Interleukin-13 binding proteins 0 2011
8,877,190 Aβ conformer selective anti-Aβ globulomer monoclonal antibodies 0 2011
8,841,417 IL-1 binding proteins 0 2011
8,735,546 Dual variable domain immunoglobulins and uses thereof 0 2011
8,664,367 IL-I binding proteins 0 2013
8,779,101 IL-17 binding proteins 0 2013
 
VACCINEX, INC. (2)
7,807,168 Selection of human TNFα specific antibodies 0 2008
8,637,026 Anti-C35 antibody combination therapies and methods 0 2008
 
LIFE TECHNOLOGIES CORPORATION (4)
7,582,461 Kinase and phosphatase assays 4 2004
7,619,059 Bimolecular optical probes 0 2004
7,727,752 Kinase and phosphatase assays 2 2006
8,067,536 Kinase and phosphatase assays 1 2010
 
SIEMENS HEALTHCARE DIAGNOSTICS INC. (1)
7,732,159 Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples 0 2007
 
BUNDESREPUBLIK DEUTSCHLAND LETZTVERTRETEN DURCH DAS ROBERT- KOCH-INSTITUT VERTRETEN DURCH SEINEN PRÄSIDENTEN (1)
8,916,155 Method for the treatment of T cell mediated conditions by depletion of ICOS-positive cells in vivo 0 2012
 
BIOGEN IDEC MA INC. (9)
7,785,829 Nogo receptor binding protein 7 2004
8,486,893 Treatment of conditions involving demyelination 1 2005
8,551,476 SP35 antibodies and uses thereof 1 2007
8,128,926 Sp35 antibodies and uses thereof 7 2009
8,058,406 Composition comprising antibodies to LINGO or fragments thereof 7 2009
8,425,910 Composition comprising antibodies to LINGO or fragments thereof 1 2011
8,609,407 Sp35 antibodies and uses thereof 1 2012
8,765,662 NOGO receptor binding protein 1 2012
8,932,821 NOGO receptor binding protein 0 2013
 
Genentech, Inc. (2)
* 6,040,136 Enrichment method for variant proteins with altered binding properties 31 1997
8,685,893 Phage display 0 2008
 
BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (2)
7,393,534 Compositions and methods for immunotherapy of cancer and infectious diseases 0 2004
8,257,714 Compositions and methods for immunotherapy of cancer and infectious diseases 0 2008
 
NATIONAL UNIVERSITY OF SINGAPORE (1)
7,060,462 AopB gene, protein,homologs, fragments and variants thereof, and their use for cell surface display 1 2001
 
BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY (2)
8,114,606 ARL-1 specific antibodies 0 2008
8,685,666 ARL-1 specific antibodies and uses thereof 0 2011
 
COSMO RESEARCH & DEVELOPMENT S.P.A. (1)
8,231,878 Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof 0 2009
 
CRUCELL HOLLAND B.V. (1)
8,568,719 Antibodies against human respiratory syncytial virus (RSV) and methods of use 0 2010
 
INSTITUT PASTEUR (2)
7,427,469 Method of treating cytomegalovirus with DC-SIGN blockers 2 2003
7,419,789 Method of inhibiting binding of Dengue virus to a human cell with DC-SIGN blockers 0 2003
 
PHYLOGICA LIMITED (5)
6,994,982 Isolating biological modulators from biodiverse gene fragment libraries 2 2000
7,270,969 Methods of constructing and screening diverse expression libraries 5 2003
7,803,765 Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom 2 2004
8,575,070 Methods of constructing and screening libraries of peptide structures 0 2007
8,822,409 Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith 0 2008
 
Human Genome Sciences, Inc. (6)
7,429,646 Antibodies to human tumor necrosis factor receptor-like 2 2 2000
7,597,886 Tumor necrosis factor-gamma 5 2001
7,820,798 Tumor necrosis factor-gamma 1 2007
7,824,675 Use of an antibody that binds human tumor necrosis factor receptor-like 2 0 2008
8,093,363 Tumor necrosis factor-gamma 0 2010
8,937,169 Human G-protein chemokine receptor HSATU68 0 2011
 
MEDIMMUNE, LLC (1)
8,852,608 Antibodies against and methods for producing vaccines for respiratory syncytial virus 0 2009
* Cited By Examiner